Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
RGEN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Repligen Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Repligen Corp ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Repligen Corp, consider:
In the past 5.38 years, Repligen Corp has a compound free cash flow growth rate of 0.25%; that's higher than 61.59% of free cash flow generating stocks in the Healthcare sector.
97% of the company's capital comes from equity, which is greater than 89.36% of stocks in our cash flow based forecasting set.
The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Repligen Corp? See BLFS, LGND, VAR, ELAN, and PCRX.
Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Financial Corp. Puneet Souda -...
* Reports record quarterly revenue of $87.5 million * Overall revenue grew 24% year-over-year, with organic growth of 19% * Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth * Completes acquisition of silicone molding and tubing manufacturer Engineered Molding TechnologyWALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call.Tony J. H...